Oestrogen therapy in trans women reduces muscle mass, strength, and haemoglobin levels significantly over time, narrowing but not eliminating the average gap with cisgender women. Surgery alone has no direct effect on athletic performance. The science is real, and more nuanced than most of the debate allows.
Why does this question matter so much right now?
Trans women in sport have become one of the most contested political topics of the last decade, which is strange when you consider how few trans women are actually competing at elite level and how little most of the people doing the arguing have read the underlying research. I have spent a long time watching this debate consume enormous emotional energy while the people at its centre, trans women who simply want to run, swim, lift, or cycle, are treated as a policy problem rather than athletes.
The physiological questions are answerable, at least partly, and they deserve a straight answer. So here is what the peer-reviewed evidence actually says about oestrogen therapy, surgery, muscle mass, strength, and athletic performance, without the political noise on either side.
What oestrogen therapy does to muscle mass
When a trans woman begins oestrogen therapy and suppresses testosterone, her body undergoes a significant hormonal shift. Testosterone is the primary driver of skeletal muscle hypertrophy, so reducing it produces a measurable decrease in muscle volume over time. The research consistently confirms this.
Studies using dual-energy X-ray absorptiometry (DEXA) scanning, which measures lean body mass and fat distribution, show that trans women lose a substantial proportion of lean mass in the first one to two years of hormone therapy. Fat redistribution also occurs, with subcutaneous fat increasing and moving toward a pattern more typical of cisgender women. These are not trivial changes. They represent a genuine physiological shift, not a cosmetic one.
What the research also shows, and what often gets left out of public debate, is that some differences in absolute lean mass persist beyond two years of therapy, particularly in people who experienced a full testosterone-driven puberty before transitioning. The reasons are partly structural: testosterone exposure during puberty influences bone density, skeletal dimensions, muscle fibre composition, and heart and lung size in ways that oestrogen therapy does not fully reverse. Height, in particular, does not change. These are real findings, and I think trans women and sport governing bodies alike deserve to hear them clearly rather than having them softened or exaggerated.
What happens to strength
Strength does not map directly onto muscle mass, but the two are closely related. Studies measuring grip strength, which is one of the most widely used proxies for overall muscular strength in research settings, show consistent reductions in trans women after oestrogen therapy. Several studies find that after one to two years of hormone therapy, grip strength in trans women moves toward the range typical of cisgender women, though averages often remain at or slightly above cisgender female averages.
A study published in the British Journal of Sports Medicine found that trans women showed significant reductions in strength and lean body mass after two years of hormone therapy, with values converging toward cisgender female norms in several measures. That is a credible finding from a credible journal, and it is representative of the direction of the evidence. I would caution against treating any single study as definitive: sample sizes in this area of research are typically small, populations are heterogeneous, and controlling for training level, age at transition, and pre-transition fitness is genuinely difficult.
The honest summary is that oestrogen therapy produces real, measurable reductions in strength over time, that values move meaningfully toward cisgender female ranges, and that some average difference may persist in certain measures in certain populations. None of that translates automatically into competitive advantage in a given sport, because sport is not a measure of average population physiology.
Haemoglobin and aerobic capacity
One of the clearest physiological effects of testosterone suppression is a reduction in haemoglobin concentration. Testosterone stimulates red blood cell production, so reducing it lowers haemoglobin, which in turn reduces oxygen-carrying capacity and has a direct effect on aerobic endurance performance.
Trans women on oestrogen therapy see haemoglobin levels fall toward cisgender female ranges, generally within the first year of treatment. This is one of the most consistent findings in the literature and one of the most physiologically significant for endurance sports such as running, cycling, and swimming. In sports where aerobic capacity is a primary determinant of performance, this change is meaningful.
What surgery does and does not do
Genital surgery, which many but not all trans women choose, has no direct physiological effect on athletic performance. It does not change muscle mass, strength, haemoglobin, bone density, lung capacity, or any other performance-relevant variable. This is not a controversial claim: it is simply anatomy. The hormonal environment is what drives the physiological changes described above, and surgery does not alter the hormonal environment in any meaningful way for athletic purposes.
Some sport governing bodies have historically required surgery as a condition of participation, a requirement that the International Olympic Committee and WPATH Standards of Care 8 have both moved away from, recognising that it has no scientific basis as a performance criterion and imposes a significant, irreversible medical intervention as the price of inclusion.
What the evidence does not yet tell us
The research in this area is genuinely limited in ways that matter. Most studies have small sample sizes. Many do not control adequately for training status, which is a huge confound: a trans woman who was a serious athlete before transition will have different baseline physiology than one who was not. Follow-up periods are often short, and most studies focus on recreational rather than elite populations.
Extrapolating from population averages to elite sport is a specific problem. Elite athletes, by definition, sit at the extreme end of the performance distribution. A finding that average grip strength in trans women after two years of therapy approximates cisgender female averages tells us relatively little about whether a specific elite trans woman has a competitive advantage over specific elite cisgender women competitors. Elite sport involves margins that population studies are not designed to detect.
The evidence supports the conclusion that oestrogen therapy produces significant physiological change that reduces performance-relevant differences. It does not currently support confident claims about whether residual differences at elite level are large enough to be decisive in competition, because the research has not been done at that scale or specificity.
What this means for sport policy
This is where I want to separate the science from the politics, because they are genuinely different questions. The science asks what oestrogen therapy does to physiology. Policy asks how sport should respond to that science in a way that is both fair and inclusive. Those are not the same question, and the science alone does not settle the policy debate.
What I will say is that policy which ignores the science is bad policy, and policy which uses science as cover for exclusion it would have chosen anyway is dishonest policy. The evidence does not support blanket exclusion of trans women from women's sport on grounds that they retain decisive physiological advantages after hormone therapy. It also does not support the claim that oestrogen therapy erases every relevant physiological difference. Both of those are political positions presented in scientific language.
Sport governing bodies making these decisions have a responsibility to commission and engage seriously with the actual evidence, to consult trans athletes rather than treating them as the subject of a problem to be managed, and to remember that inclusion is a value, not just a concession. Most trans women competing in sport are doing so at recreational or amateur level, seeking the same things anyone seeks from sport: fitness, community, joy, and competition. The elite cases that dominate the political debate represent a tiny fraction of trans women in sport.
The person in the middle of all this
I have spoken with many trans women who love sport and have found themselves unable to compete, or unwilling to put themselves through the scrutiny and hostility that competing now involves. That is a real harm. Sport is good for physical health, for mental health, for belonging. Excluding people from it, or making them feel so unwelcome that they exclude themselves, has costs that the policy debate rarely accounts for.
The physiological evidence should inform sport policy, not be weaponised to justify a predetermined conclusion. Trans women deserve the same access to sport, to competition, and to the communities sport creates, that anyone else does. That does not require pretending the science is settled where it is not. It requires engaging honestly with what it does say, which is that oestrogen therapy produces meaningful physiological change, that some differences may persist, that those differences vary enormously between individuals, and that none of this is a simple story.
Comments